Asymmetric Outcomes of Type 1 Retinopathy of Prematurity after Bilateral Intravitreal Ranibizumab Treatment.
Asymmetric Outcomes of Type 1 Retinopathy of Prematurity after Bilateral Intravitreal Ranibizumab Treatment.
复制标题
双侧玻璃体内雷珠单抗治疗后 1 型早产儿视网膜病变的不对称结果
DOI：
10.1155/2017/1741386
复制
发表时间：
2017
影响因子：
1.9
通讯作者：
Zhao P
中科院分区：
文献类型：
--
作者：
Huang Q;Zhang Q;Xu Y;Ji X;Fei P;Peng J;Li YA;Zhao P
目的.介绍接受玻璃体内注射雷珠单抗（IVR）治疗的早产儿视网膜病变（ROP）病例，这些病例具有不可预测的不对称结局。方法.对1型ROP婴儿进行了回顾性分析，并将双侧IVR（0.25 mg/0.025 mL）作为初始治疗。患者分为不对称结局组和对称结局组。结果84例患者（168只眼）入选。结果不对称组9例18眼（10.7%），结果对称组75例150眼（89.3%）。在对称结局组中，86只眼（57.3%）发生ROP消退，60只眼（40%）发生需要激光治疗的再激活，4只眼（2.7%）进展为需要玻璃体切除术的视网膜脱离。在不对称结局组中，9例患者的其中一只眼在IVR后有ROP消退伴/不伴再激活，而对侧眼反应阴性，包括明显的后纤维化、部分或全部视网膜脱离和玻璃体积血。两组新生儿出生体重差异有统计学意义。结论雷珠单抗治疗后，患有ROP的对侧眼可能会出现不同的临床病程。IVR后高的再激活率是眼科医生应该注意的另一个问题。
Purpose. To present cases with retinopathy of prematurity (ROP), who were treated with intravitreal injection of ranibizumab (IVR) and had unpredictable asymmetric outcomes. Methods. A retrospective review was performed in infants with type 1 ROP and had bilateral IVR (0.25 mg/0.025 mL) as initial treatment. Patients were classified into the asymmetric outcome group and the symmetric outcome group. Results. Eighty-four patients (168 eyes) were included. There were 18 eyes of 9 patients (10.7%) in the asymmetric outcome group and 150 eyes of 75 patients (89.3%) in the symmetric outcome group. In the symmetric outcome group, 86 eyes (57.3%) had ROP regression, 60 eyes (40%) had reactivation requiring laser treatment, and 4 eyes (2.7%) progressed to retinal detachment requiring vitrectomy. In the asymmetric outcome group, one of the eyes of the 9 patients had ROP regression with/without reactivation after IVR, while the contralateral eyes had negative response, including remarkable posterior fibrosis, partial or total retinal detachment, and vitreous hemorrhage. There was statistically significant difference between the birth weight of the two groups. Conclusion. Contralateral eyes with ROP can take a different clinical course after ranibizumab treatment. High rate of reactivation after IVR is another concern that ophthalmologists should pay attention to.